Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

The specialised, focused library is developed on demand with the most recent virtual screening and parameter assessment technology, guided by the Receptor.AI drug discovery platform. This approach exceeds the capabilities of traditional methods and offers compounds with higher activity, selectivity, and safety.


Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by Reaxense.


In the library, a selection of top modulators is provided, each marked with 38 ADME-Tox and 32 parameters related to physicochemical properties and drug-likeness. Also, every compound comes with its best docking poses, affinity scores, and activity scores, providing a comprehensive overview.


We utilise our cutting-edge, exclusive workflow to develop focused libraries for enzymes.


 

Fig. 1. The screening workflow of Receptor.AI

The method includes detailed molecular simulations of the catalytic and allosteric binding pockets, along with ensemble virtual screening that considers their conformational flexibility. In the design of modulators, structural changes induced by reaction intermediates are taken into account to enhance activity and selectivity.


Several key aspects differentiate our library:


  • Receptor.AI compiles an all-encompassing dataset on the target protein, including historical experiments, literature data, known ligands, and structural insights, maximising the chances of prioritising the most pertinent compounds.

  • The platform employs state-of-the-art molecular simulations to identify potential binding sites, ensuring the focused library is primed for discovering allosteric inhibitors and binders of concealed pockets.

  • Over 50 customisable AI models, thoroughly evaluated in various drug discovery endeavours and research projects, make Receptor.AI both efficient and accurate. This technology is integral to the development of our focused libraries.

  • In addition to generating focused libraries, Receptor.AI offers a full range of services and solutions for every step of preclinical drug discovery, with a pricing model based on success, thereby reducing risk and promoting joint project success.


PARTNER
Receptor.AI
 
UPACC
A6NNW6

UPID:
ENO4_HUMAN

ALTERNATIVE NAMES:
2-phospho-D-glycerate hydro-lyase

ALTERNATIVE UPACC:
A6NNW6; A0A087WZY6; A6NI74; B8ZZN9; J3KNX1

BACKGROUND:
The protein Enolase 4, with its alternative name 2-phospho-D-glycerate hydro-lyase, is implicated in critical biological functions, notably in the realm of sperm motility and function. This suggests its involvement in the intricate processes of energy metabolism and cellular regulation.

THERAPEUTIC SIGNIFICANCE:
Exploring the functions of Enolase 4 offers a promising avenue for therapeutic intervention. Given its essential role in sperm function, research into Enolase 4 could yield innovative approaches to addressing reproductive challenges, potentially revolutionizing treatments for conditions affecting male fertility.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.